Slanix Paul Alex - 22 Oct 2025 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
Director
Signature
/s/ Max A. Milbury, Attorney-in-Fact
Issuer symbol
PMN
Transactions as of
22 Oct 2025
Net transactions value
$0
Form type
3
Filing time
24 Oct 2025, 16:30:21 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Alex Slanix Paul Director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO, ONTARIO, CANADA /s/ Max A. Milbury, Attorney-in-Fact 24 Oct 2025 0002092283

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMN Common Shares 6,058,738 22 Oct 2025 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMN Warrants 22 Oct 2025 Common Shares 174,759 $0.0100 See Footnote F1, F2
holding PMN Warrants 22 Oct 2025 Common Shares 1,066,674 $1.75 See Footnote F1
holding PMN Warrants 22 Oct 2025 Common Shares 1,100,000 $0.0100 See Footnote F1, F2
holding PMN Warrants 22 Oct 2025 Common Shares 7,348,604 $1.25 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. The Reporting Person is a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.
F2 The warrants will expire when exercised in full.

Remarks:

Exhibit 24 - Power of Attorney